ATTAIN-1 — structured trial abstract

§1Structured abstract

§1.1Objective

To evaluate Orforglipron in obesity and overweight in adults, against the comparator specified in §2, with the primary endpoint stated below.

§1.2Design

Design

Randomised, double-blind, placebo-controlled, parallel-group

Masking

Double-blind (participant, investigator and sponsor)

Phase

Phase 3

Randomised participants

not recorded by the Institute

Duration of the primary analysis period

72 weeks

Sponsor class

Manufacturer-sponsored

Registry identifier

not reproduced — see the note in §1.5

§1.3Primary endpoint

Percentage change in body weight from baseline to week 72

§1.4Principal result

The Institute holds a headline result indicating a weight effect intermediate between the injectable single agonists and placebo, and awaits the full publication before reproducing a point estimate.

The Institute does not reproduce an effect estimate from a press release. Where only a sponsor announcement exists, the monograph says so.

§1.5Provenance of this abstract

Table 1. Field-by-field provenance. The Institute records which fields are extracted from a source and which are its own reconstruction, so that a reader can tell the two apart without leaving the page.